VivoSim Labs (NASDAQ:VIVS) Trading Down 0.3% – What’s Next?

VivoSim Labs, Inc. (NASDAQ:VIVS) traded down 0.3% during mid-day trading on Thursday . The stock traded as low as $0.2720 and last traded at $0.2790. 605,036 shares changed hands during trading, a decline of 90% from the average daily volume of 6,314,533 shares. The stock had previously closed at $0.2798.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VivoSim Labs in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

VivoSim Labs Trading Down 0.3%

The stock’s 50-day moving average price is $0.50 and its 200-day moving average price is $1.17. The company has a market capitalization of $4.62 million, a P/E ratio of -0.06 and a beta of 1.45.

VivoSim Labs (NASDAQ:VIVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.25) earnings per share for the quarter. VivoSim Labs had a negative net margin of 11,016.07% and a negative return on equity of 612.23%. The business had revenue of $0.02 million for the quarter.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs at the end of the most recent reporting period. 8.23% of the stock is currently owned by hedge funds and other institutional investors.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.